Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

Download Publication on intranasal sprays for respiratory viral infections
28 Jan 2022

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

1 May 2020

Supporting Improved Patient Onboarding and Adherence with Training Solutions

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
21 Apr 2020

Using in vitro dissolution tests for local bioequivalence in OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights

Read More
1 Apr 2020

Demonstrating bioequivalence in generic orally inhaled drug products

Publications, Pharmaceutical, Innovation & Insights

Read More
1 Apr 2020

Patient training and onboarding for intranasal rescue treatments

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 22 23 24 25 26 27

Request Access

Close

Requesting access to Improving Intranasal Sprays for Respiratory Viral Infections.

  • This field is for validation purposes and should be left unchanged.
Back To Top